共 75 条
[1]
Fahn S(2004)Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498-2508
[2]
Oakes D(2009)Ropinirole prolonged release: in advanced Parkinson's disease CNS Drugs 23 81-90
[3]
Shoulson I(2007)Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease Neurology 68 1108-1115
[4]
Weber J(1999)Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study J Neurol Neurosurg Psychiatry 66 436-441
[5]
Keating GM(2013)Evidence synthesis for decision making 3: heterogeneity–subgroups, meta-regression, bias, and bias-adjustment Med Decis Making 33 618-640
[6]
Pahwa R(2007)Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial Lancet Neurol 6 513-520
[7]
Stacy MA(1998)A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease Eur J Neurol 5 235-242
[8]
Factor SA(2005)Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial Mov Disord 20 602-610
[9]
Pinter MM(2011)Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial Neurology 77 767-774
[10]
Pogarell O(2003)Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease J Neurol Sci 216 81-87